Loading stock data…
Ernexa Therapeutics Inc. (ERNA)
$4.19-0.12 (-2.78%)
Market ClosedLast close Sep 8
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ernexa Therapeutics Inc. in the Healthcare sector is trading at $4.19 with a market capitalization of $8M. Wall Street consensus targets $30.00 (1 analysts), implying a +616.0% move over the next 12 months. The stock is currently near its 52-week low of $3.18, remaining 67.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +616.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$3.55M↓ | -$2.09M↓ | -$1.99M↑ | -$2.50M↑ | -$2.73M |
| Net Income | -$5.51M↓ | -$1.50M↓ | -$1.24M↑ | -$3.14M↑ | -$8.20M |
Peer Comparison
JNJUNHPFE
Fundamentals
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflamma...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.20M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
0.01
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.47
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-166.02%
Volume
Today's trading volume
18,187
Recent News
Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA)
Ernexa Therapeutics (NASDAQ:ERNA) shares surged 30% on Wednesday after the company announced positive independent preclinical data supporting its lead cell therapy candidate, ERNA-101, for the treatment of ovarian cancer. Independent research confirms earlier findingsThe company said an independent contract research organisation successfully replicated previous results, demonstrating complete tumour clearance and extended survival in a larger preclinical study.
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know
Ernexa Therapeutics stock soars 140% in a month as ERNA-101 shows complete tumor clearance and long-term survival in pre-clinical ovarian cancer models.
Trump Rattled Markets Again and These 3 Forgotten Stocks Under $30 Were the Unlikely Winners
President Trump’s 12-word remark, “I don’t think about Americans’ financial situation, I don’t think about anybody,” hit the wires, and the reaction showed up in the forgotten corners of the market, where micro-cap turnarounds priced like option contracts ripped higher on May 15 as traders rotated into beaten-down names with operational catalysts already in motion. ... Trump Rattled Markets Again and These 3 Forgotten Stocks Under $30 Were the Unlikely Winners
Ernexa Therapeutics (ERNA) Preclinical Data Shows 100% Survival and Complete Tumor Clearance in Ovarian Cancer Models
Ernexa Therapeutics reported new preclinical findings showing its ERNA-101 cell therapy candidate achieved complete tumor elimination and long-term survival in ovarian cancer models when combined with PD-1 blockade. Key Investor TakeawaysErnexa Therapeutics (NASDAQ:ERNA) released preclinical ovarian cancer data showing ERNA-101 achieved complete tumor clearance and 100% survival in treated mice.
BC-Most Active Stocks
YY Group Holdings Ltd. 56,330,377 0.4678